Global Macular Degeneration Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Disease Indication;
Dry Age-Related Macular Degeneration (DAMD), and Wet Age-Related Macular Degeneration (WAMD).By Distribution Channel;
Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers.By Route of Administration;
Intravenous Route, Intravitreal Route, Others.By Drug;
Anti-Vascular Endothelial Growth Factors, Others.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global Macular Degeneration Treatment Market (USD Million), 2021 - 2031
In the year 2024, the Global Macular Degeneration Treatment Market was valued at USD 9,745.26 million. The size of this market is expected to increase to USD 15,546.67 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.9%.
Macular degeneration, a leading cause of vision loss among older adults, particularly those over the age of 50, presents a significant public health challenge globally. This degenerative eye disease affects the macula, a region of the retina responsible for central vision, leading to blurred or distorted vision and, in severe cases, irreversible vision loss. As the aging population continues to grow worldwide, the prevalence of macular degeneration is expected to rise, driving the demand for effective treatments and interventions. Understanding the market dynamics, including the latest advancements in treatment modalities, emerging trends, and key players, is crucial for stakeholders ranging from healthcare providers to pharmaceutical companies and policymakers to develop strategies aimed at addressing the growing burden of macular degeneration.
The Global Macular Degeneration Treatment Market encompasses a wide range of therapeutic approaches, including pharmacological interventions, laser therapy, and surgical procedures, aimed at slowing disease progression, preserving vision, and improving patient outcomes. Pharmacological treatments, such as anti-vascular endothelial growth factor (anti-VEGF) injections and oral supplements, have emerged as standard-of-care options for managing macular degeneration, offering significant benefits in terms of vision stabilization and, in some cases, improvement. Advancements in gene therapy and regenerative medicine hold promise for addressing the underlying molecular mechanisms of macular degeneration, paving the way for potential disease-modifying treatments. With ongoing research and clinical trials focusing on novel treatment modalities and personalized approaches, the Global Macular Degeneration Treatment Market is poised for continued growth and innovation, offering hope for millions of individuals affected by this sight-threatening condition.
Global Macular Degeneration Treatment Market Recent Developments
-
In August 2022, The Philippine FDA approved Novartis' brolucizumab for treating neovascular (wet) age-related macular degeneration (AMD). This approval marked a significant advancement in AMD therapy, providing patients with a new option for managing this serious eye condition.
-
In June 2022, Health Canada approved Roche's VABYSMO (faricimab injection) for the treatment of neovascular (wet) age-related macular degeneration (AMD). This decision marked a significant advancement in therapeutic options for patients suffering from this serious eye condition.
Segment Analysis
Age-related macular degeneration (AMD) is a leading cause of vision loss, and it can be categorized into dry AMD and wet AMD. Dry AMD, or Dry Age-Related Macular Degeneration (DAMD), is the more common form, typically progressing slowly and leading to gradual vision loss. Wet AMD, or Wet Age-Related Macular Degeneration (WAMD), is less common but more severe, characterized by the growth of abnormal blood vessels beneath the retina, which can lead to rapid vision deterioration. Treatments for these conditions primarily focus on slowing progression and preserving vision, with different therapies targeted to the underlying mechanisms of each form.
The distribution of AMD treatments spans various channels, with hospitals, ophthalmic clinics, and ambulatory surgical centers being key providers. Hospitals often offer comprehensive diagnostic and treatment services, handling both severe cases and advanced treatments. Ophthalmic clinics specialize in eye care and provide more personalized treatment options, focusing on the management of AMD and other retinal diseases. Ambulatory surgical centers, which focus on outpatient care, increasingly perform procedures like intravitreal injections for wet AMD, offering patients convenient and less invasive treatment options in a specialized setting.
The route of administration for AMD treatments varies, with intravenous and intravitreal routes being the most common. Intravenous administration is typically used for systemic treatments that target vascular endothelial growth factors, while intravitreal injections are more commonly used for localized treatment of wet AMD, directly delivering the drug to the site of action within the eye. Anti-vascular endothelial growth factors (anti-VEGFs) are the primary class of drugs used for treating wet AMD, aiming to inhibit the growth of abnormal blood vessels and prevent further vision loss. Other drugs may also be used for managing both forms of AMD, depending on the severity and individual patient needs.
Global Macular Degeneration Treatment Segment Analysis
In this report, the Global Macular Degeneration Treatment Market has been segmented by Disease Indication, Distribution Channel,Route of Administration,Drug, and Geography.
Global Macular Degeneration Treatment Market, By Disease Indication
The Global Macular Degeneration Treatment Market has been segmented by Disease Indication into Dry Age-related Macular Degeneration (dAMD) and Wet Age-related Macular Degeneration (wAMD).
Dry AMD, characterized by the gradual breakdown of light-sensitive cells in the macula, constitutes a significant portion of the market. While treatment options for dry AMD are limited compared to wet AMD, there is a growing emphasis on disease management strategies such as lifestyle modifications, nutritional supplements, and potential emerging therapies aimed at slowing disease progression and preserving vision. Wet AMD, characterized by abnormal blood vessel growth beneath the retina, presents more immediate and severe vision loss if left untreated. The market for wet AMD treatments is characterized by a range of therapeutic interventions including anti-vascular endothelial growth factor (anti-VEGF) injections, photodynamic therapy, and emerging therapies targeting different aspects of the disease pathway.
While the wet AMD market is characterized by the dominance of anti-VEGF therapies and ongoing research into alternative treatment modalities, the dry AMD market presents opportunities for breakthrough innovations in disease-modifying therapies. With the aging population contributing to the rising prevalence of macular degeneration globally, there is an increasing focus on early detection, diagnosis, and patient education initiatives across both disease indications. Collaborative efforts between stakeholders to address unmet needs in both dry and wet AMD treatment markets are essential for improving patient outcomes and mitigating the socioeconomic burden associated with this sight-threatening condition.
Global Macular Degeneration Treatment Market, By Distribution Channel
The Global Macular Degeneration Treatment Market has been segmented by Distribution Channel into Hospitals, Ophthalmic Clinics and Ambulatory Surgical Centers.
Hospitals, as primary centers for healthcare delivery, play a pivotal role in providing comprehensive macular degeneration treatment services. With advanced medical infrastructure and multidisciplinary teams of healthcare professionals, hospitals offer a wide range of treatment options, including intravitreal injections, laser therapy, and surgical interventions, catering to patients with varying degrees of disease severity. Hospitals often serve as referral centers for complex cases, providing access to specialized equipment and expertise for optimal management of macular degeneration complications. The centralized nature of hospital-based care ensures coordinated treatment pathways and facilitates continuity of care for patients throughout their disease journey.
Ophthalmic clinics, specializing in eye care services, constitute another vital distribution channel for the Global Macular Degeneration Treatment Market. These clinics are dedicated to the diagnosis, treatment, and management of various ophthalmic conditions, including macular degeneration. With a focus on ocular health and vision preservation, ophthalmic clinics offer specialized expertise and state-of-the-art diagnostic technologies for early detection and monitoring of macular degeneration. These clinics often provide tailored treatment plans and patient education programs, empowering individuals to actively participate in their eye health management. Ambulatory surgical centers, characterized by their outpatient setting and specialized surgical capabilities, play a crucial role in delivering surgical interventions such as vitrectomy and macular translocation surgeries for select patients with advanced stages of macular degeneration.
Global Macular Degeneration Treatment Market, By Route of Administration
The Global Macular Degeneration Treatment Market has been segmented by Route of Administration into Intravenous Route, Intravitreal Route, Others.
The route of administration plays a crucial role in determining the effectiveness and safety of treatments, especially in conditions like age-related macular degeneration (AMD). The intravenous route is commonly used for systemic treatments, where the drug is delivered directly into the bloodstream. This approach ensures that the medication is distributed throughout the body, allowing it to target various organs or tissues. For conditions like AMD, intravenous treatments can address systemic factors that contribute to the disease, such as inflammation or the formation of abnormal blood vessels.
The intravitreal route is specific to eye conditions, where the drug is injected directly into the vitreous humor of the eye. This route is particularly effective for treating wet AMD, as it allows for high local concentrations of medication to target the abnormal blood vessels beneath the retina. Intravitreal injections are preferred for their ability to provide more direct and potent effects in the eye, reducing systemic side effects. This method is also commonly used for delivering anti-VEGF therapies, which inhibit the growth of new blood vessels and prevent further damage to the retina.
Other routes of administration may also be employed depending on the treatment needs and specific conditions. For example, some treatments may be administered topically, such as eye drops for less severe forms of eye disease, or even through oral tablets in cases where systemic treatment is required but local delivery is not feasible. The choice of route depends on factors like the type and severity of the disease, patient preference, and the potential side effects associated with each method.
Global Macular Degeneration Treatment Market, By Drug
The Global Macular Degeneration Treatment Market has been segmented by Drug into Anti-Vascular Endothelial Growth Factors, Others.
Anti-vascular endothelial growth factor (anti-VEGF) drugs are the cornerstone of treatment for wet age-related macular degeneration (WAMD). These drugs work by inhibiting the activity of VEGF, a protein that promotes the growth of abnormal blood vessels in the retina. By blocking VEGF, these treatments prevent further vascular leakage and growth of these vessels, which can lead to severe vision loss. Anti-VEGF therapies are administered via intravitreal injections, which deliver the medication directly into the eye, ensuring localized action and reducing systemic side effects.
In addition to AMD, anti-VEGF drugs are also used for other ocular conditions characterized by abnormal blood vessel growth, such as diabetic retinopathy and retinal vein occlusion. These conditions can lead to significant vision impairment, and anti-VEGF therapies help stabilize or even improve vision in many patients. The effectiveness of anti-VEGF treatments has revolutionized the management of these retinal diseases, making them a vital tool in preserving eyesight in patients with these conditions.
Other drugs used in the treatment of retinal diseases may target different mechanisms of disease. These treatments could include corticosteroids, which reduce inflammation in the eye, or newer agents that address other aspects of vascular health or cell signaling in the retina. While anti-VEGF drugs remain the most widely used for conditions like wet AMD, ongoing research is exploring additional pharmacological options that could provide complementary benefits or offer new treatment avenues for patients who may not respond to anti-VEGF therapies alone.
Global Macular Degeneration Treatment Market, By Geography
In this report, the Global Macular Degeneration Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Macular Degeneration Treatment Market Share (%), by Geographical Region, 2024
North America, comprising the United States and Canada, emerges as a dominant market due to advanced healthcare systems, high prevalence rates of macular degeneration, and significant investments in research and development. The presence of key market players, academic institutions, and government initiatives focused on vision health further propels market growth in this region. Europe follows suit with countries like Germany, the United Kingdom, and France playing pivotal roles in the market, supported by comprehensive healthcare policies, increasing aging population, and rising awareness about eye diseases. The region also benefits from collaborations between industry stakeholders and healthcare organizations aimed at advancing treatment options and improving patient outcomes.
In the Asia Pacific region, countries such as China, India, and Japan are witnessing rapid growth in the macular degeneration treatment market fueled by factors such as increasing healthcare spending, expanding healthcare infrastructure, and growing demand for innovative therapies. Government initiatives aimed at promoting eye health, along with rising awareness about preventive measures and early diagnosis, further contribute to market expansion. The Middle East and Africa present opportunities for market players to address unmet medical needs and improve access to treatment through strategic partnerships and collaborations with local healthcare providers. Latin America showcases promising growth potential, with countries like Brazil, Mexico, and Argentina witnessing increasing adoption of advanced treatment modalities and rising investment in vision care.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Macular Degeneration Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Development of novel pharmaceuticals and biologics
- Collaborations between industry and research institutions
- Growing awareness about eye health
-
Improvements in diagnostic techniques - In the context of macular degeneration, advancements such as optical coherence tomography (OCT), fundus autofluorescence imaging, and fluorescein angiography have revolutionized the way clinicians assess and monitor retinal health. These techniques enable detailed visualization of the macula, allowing for early detection of pathological changes such as drusen formation, retinal pigment epithelial alterations, and choroidal neovascularization.
Advancements in image processing algorithms and artificial intelligence have facilitated automated analysis of imaging data, leading to improved accuracy and efficiency in diagnosing macular degeneration. By enabling timely and precise diagnosis, these diagnostic techniques play a crucial role in initiating appropriate treatment interventions and optimizing patient outcomes in the management of macular degeneration.
Restraints
- Safety concerns with long-term medication use
- Lack of awareness about treatment options
-
Limited availability of specialized equipment -Access to advanced imaging modalities such as OCT, fundus cameras, and angiography systems may be restricted in underserved areas due to factors such as high cost, limited healthcare funding, and inadequate training of healthcare personnel. As a result, patients in these regions may experience delays in receiving timely diagnosis and appropriate management of macular degeneration, leading to potentially irreversible vision loss.
Addressing the issue of limited equipment availability requires collaborative efforts between governments, non-profit organizations, and private sector stakeholders to invest in healthcare infrastructure, provide training programs for healthcare professionals, and facilitate access to essential diagnostic and treatment technologies. By improving the accessibility of specialized equipment, healthcare disparities can be reduced, and more individuals affected by macular degeneration can receive the care they need to preserve their vision and quality of life.
Opportunities
- Expansion of clinical trial participation
- Customization of treatment plans based on genetic profiling
- Utilization of combination therapies for synergistic effects
-
Development of sustained-release drug delivery systems -The development of sustained-release drug delivery systems represents a significant advancement in pharmaceutical technology, offering prolonged and controlled release of medications to patients. These systems utilize various formulations and mechanisms, such as encapsulation in biodegradable polymers or implantable devices, to slowly release therapeutic agents over an extended period.
By delivering drugs steadily at a predetermined rate, sustained-release systems help maintain therapeutic concentrations within the body, minimizing fluctuations and reducing the frequency of dosing. This not only enhances patient convenience and compliance but also improves therapeutic efficacy and safety by avoiding peak and trough drug levels associated with conventional dosing regimens. Sustained-release formulations can provide targeted delivery to specific tissues or organs, optimizing drug distribution and minimizing systemic side effects.
Competitive Landscape Analysis
Key players in Global Macular Degeneration Treatment Market include
- Novartis
- GlaxoSmithKline
- Bayer
- Ophthotech Corporation
- Neurotech Pharmaceuticals
- StemCells
- Allergan
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Disease Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Route of Administration
- Market Snapshot, By Drug
- Market Snapshot, By Region
- Global Macular Degeneration Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Development of novel pharmaceuticals and biologics
- Collaborations between industry and research institutions
- Growing awareness about eye health
- Improvements in diagnostic techniques
- Restraints
- Safety concerns with long-term medication use
- Lack of awareness about treatment options
- Limited availability of specialized equipment
- Opportunities
- Expansion of clinical trial participation
- Customization of treatment plans based on genetic profiling
- Utilization of combination therapies for synergistic effects
- Development of sustained-release drug delivery systems
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Macular Degeneration Treatment Market, By Disease Indication, 2021 - 2031 (USD Million)
- Dry Age-related Macular Degeneration (dAMD)
- Wet Age-related Macular Degeneration (wAMD)
- Global Macular Degeneration Treatment Market, By Distribution Channel, 2021 - 2031 (USD Million)
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgical Centers
- Global Macular Degeneration Treatment Market, By Route of Administration, 2021 - 2031 (USD Million)
- Intravenous Route
- Intravitreal Route
- Others
- Global Macular Degeneration Treatment Market, By Drug, 2021 - 2031 (USD Million)
- Anti-Vascular Endothelial Growth Factors
- Others
- Global Macular Degeneration Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Macular Degeneration Treatment Market, By Disease Indication, 2021 - 2031 (USD Million)
- Competitive Landscape Analysis
- Company Profiles
- Novartis
- GlaxoSmithKline
- Bayer
- Ophthotech Corporation
- Neurotech Pharmaceuticals
- StemCells
- Allergan
- Company Profiles
- Analyst Views
- Future Outlook of the Market